bendamustine hydrochloride has been researched along with B-Cell Lymphoma in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (8.33) | 29.6817 |
| 2010's | 48 (66.67) | 24.3611 |
| 2020's | 18 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishikawa, T; Makita, M; Moriyama, T; Murakami, H; Sunami, K; Yoshioka, T | 1 |
| Cai, Z; He, D; He, J; Huang, W; Yang, Y; Zhang, Y; Zhao, Y | 1 |
| Jiang, T; Ou, W; Tang, X | 1 |
| Andriani, A; Autore, F; Cimino, G; Del Poeta, G; Ditto, C; Fresa, A; Innocenti, I; Laurenti, L; Maglione, R; Mauro, FR; Mengarelli, A; Padua, L; Papa, E; Pelliccia, S; Principe, MID; Romeo, A; Stefanizzi, C; Tafuri, A | 1 |
| Aurer, I; Babic, A; Batinic, D; Lalic, H; Smoljo, T; Visnjic, D | 1 |
| Butera, J; Egan, P; MacKinnon, K; Margolis, J; McMahon, J; Ollila, T; Olszewski, AJ; Reagan, J; Rosati, V; Thomas, A; Yakirevich, I | 1 |
| Chandler, JC; Davis, J; Forero-Torres, A; Hoever, P; Iyer, SP; Izquierdo, M; Kanate, AS; Madan, S; Quinlan, M | 1 |
| Dote, S; Goto, R; Inose, R; Kobayashi, Y; Muraki, Y | 1 |
| Jentsch-Ullrich, K; Schalk, E | 1 |
| Fan, L; Jiang, R; Li, JY; Mi, HL; Miao, Y; Qin, SC; Qiu, JY; Sha, YQ; Wang, L; Wu, W; Xu, W; Zhu, HY | 1 |
| Baltasar Tello, P; Bravo, J; Champ, D; Delgado, J; Fernández Zarzoso, M; Forés, R; Garcia-Marco, JA; Gironella, M; González Garcia, E; Medina Perez, A; Páyer, AR; Ríos Herranz, E; Terol Castera, MJ | 1 |
| Du, KX; Li, JY; Li, Y; Liang, JH; Shen, HR; Wang, L; Wu, JZ; Xia, Y; Xu, W; Yin, H | 1 |
| Butera, JN; Castillo, JJ; Olszewski, AJ; Reagan, JL | 1 |
| Amaya, ML; Jimeno, A; Kamdar, M | 1 |
| Ito, S; Izumiyama, K; Kakinoki, Y; Kondo, T; Shimono, J; Teshima, T; Tsutsmi, Y | 1 |
| Izumi, T; Kato, S; Kawamura, T; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Nagao, S; Ogata, H; Okada, Y; Saito, K; Sato, K; Sone, T; Tachi, N; Takada, K; Takano, K; Teramoto, M | 1 |
| Chen, P; Gan, Y; Gao, F; He, X; Li, S; Lin, L; Qian, W; Qiu, X; Tong, J; Xu, Y; Yu, T; Zhang, J; Zhang, X | 1 |
| Angelopoulou, MK; Arapaki, M; Banti, A; Bouzani, M; Chatzileontiadou, S; Dalekou-Tsolakou, M; Dimou, M; Giannouli, S; Hatzimichael, E; Iliakis, T; Kalpadakis, C; Katodritou, E; Konstantinidou, P; Konstantopoulos, K; Kyrtsonis, MC; Mandala, E; Marinakis, T; Mparmparousi, D; Panayiotidis, P; Papageorgiou, SG; Pappa, V; Poziopoulos, C; Sachanas, S; Siakantaris, MP; Sioni, A; Spanoudakis, E; Stavroyianni, N; Tsirkinidis, P; Tsirogianni, M; Vadikolia, C; Vassilakopoulos, TP; Verrou, E; Vervessou, E; Violaki, V; Ximeri, M | 1 |
| Barr, PM; James, L; Kahl, B; Martin, P; Pathak, A | 1 |
| Iwasaki, H; Kadowaki, M; Kohno, K; Takase, K; Yamasaki, S | 1 |
| Brown, JR; Danilov, AV; Gordon, MJ; Lewis, LD | 1 |
| Ghesani, N; Khodarahmi, I | 1 |
| Castillo, JJ; Olszewski, AJ; Reagan, JL | 1 |
| Goyle, S; Parikh, P; Singhania, SVK | 1 |
| Carli, G; D'Amore, ESG; Di Bona, E; Famengo, B; Paolini, R; Perbellini, O; Piazza, F; Ravelli, E; Ruggeri, M; Sartori, R; Tecchio, C; Tisi, MC; Visco, C | 1 |
| Dreyling, M; Gafter-Gvili, A; Gurion, R; Shargian, L; Vidal, L | 1 |
| Chinen, Y; Fuchida, SI; Horiike, S; Iwai, T; Kaneko, H; Kawata, E; Kiyota, M; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakao, M; Nishigaki, H; Ohshiro, M; Shimazaki, C; Shimura, K; Shimura, Y; Sugitani, M; Takimoto-Shimomura, T; Taniwaki, M; Uchiyama, H; Uoshima, N; Yoshida, M | 1 |
| Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E | 1 |
| Masood, N; Osmani, AH | 1 |
| Fesler, MJ; Hyder, MA; Parker, SM | 1 |
| Chen, LS; Gandhi, V; Neelapu, SS; Yang, Q | 1 |
| Kawashima, I; Kirito, K; Mitsumori, T; Nakajima, K; Nozaki, Y; Sueki, Y; Yamamoto, T | 1 |
| Izutsu, K; Maruyama, D; Nisikori, M; Ohmachi, K; Suzuki, T | 1 |
| Cheng, H; Cheng, Z; Xie, F; Yu, P | 1 |
| Bellam, N; Eisenfeld, AJ; Feldman, T; Gopal, AK; Goy, A; Green, DJ; Griffin, M; Mato, AR; Stromatt, SC; Tarantolo, SR | 1 |
| Fallon, MJ; Heck, JN | 1 |
| Aisa, Y; Hasegawa, T; Nakazato, T; Shimazaki, K | 1 |
| Chen, PM; Chiou, TJ; Hou, HA; Hsiao, LT; Kuo, CY; Liu, CY; Tien, HF; Wang, MC; Wu, JH | 1 |
| Bron, D; Czuczman, MS; Davis, G; Forero, A; Fowler, N; Kahanic, S; Munteanu, M; Offner, F; Quick, D; Van Den Neste, E | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| Aisa, Y; Chen, K; Hagihara, M; Ishida, A; Masuda, Y; Matsumoto, K; Miyakawa, Y; Nakajima, H; Nakaya, A; Nakazato, T; Okamoto, S; Shimizu, T; Takayama, N; Tsukada, Y; Ueno, H; Watanabe, K; Yamada, Y; Yano, T; Yokoyama, K | 1 |
| Haga, H; Hishizawa, M; Kadowaki, N; Kawabata, H; Kitano, T; Kitawaki, T; Kobayashi, M; Kondo, T; Nishikori, M; Takaori-Kondo, A; Takei, Y; Yamashita, K | 1 |
| Abhayankar, S; Aljitawi, O; Diaz, F; Divine, C; Ganguly, S; Iliff, A; McGuirk, J | 1 |
| Fukuhara, S; Kitahara, H; Kobayashi, Y; Maeshima, AM; Makita, S; Maruyama, D; Miyamoto, K; Munakata, W; Saito, H; Suzuki, T; Taniguchi, H; Tobinai, K | 1 |
| Li, J; Xu, W; Zhu, H | 1 |
| Asano, C; Imai, Y; Inokuchi, K; Isono, N; Kazama, H; Masuda, M; Mitsuhashi, K; Moriya, K; Motoji, T; Shimura, H; Sugimori, H; Tamura, H; Tanaka, J; Watanabe, A | 1 |
| Berardi Vilei, S; Cairoli, A; Caspar, CB; Eckhardt, K; Enoiu, M; Fischer, N; Hitz, F; Krasniqi, F; Mach, N; Mey, U; Pabst, T; Rondeau, S; Rothermundt, C; Samaras, P; Schmidt, A; Zucca, E | 1 |
| Awan, FT; Costa, LJ; Gao, L; Gore, L; Lager, J; Sharma, J | 1 |
| Munakata, W; Tobinai, K | 1 |
| Cheson, BD; Cohen, P; Herst, JA; Lemieux, B; Robinson, KS; Schwartzberg, LS; Tulpule, A; van der Jagt, RH; Williams, ME | 1 |
| Franke, I; Gollnick, H; Leverkus, M; Mleczko, A; Scheinpflug, K | 1 |
| Bartlett, NL; Chen, L; Cheson, BD; Czuczman, MS; Ganjoo, K; Joyce, R; Kahl, BS; Leonard, JP; Robinson, KS; van der Jagt, RH; Williams, ME | 1 |
| Dennie, TW; Kolesar, JM | 1 |
| Ando, K; Kasai, M; Matsumoto, Y; Ogawa, Y; Ogura, M; Ohmachi, K; Shimizu, D; Taniwaki, M; Tobinai, K; Uchida, T; Watanabe, T; Yokoyama, H | 1 |
| Ando, K; Choi, I; Ishizawa, K; Itoh, K; Kubota, N; Nagai, H; Ogura, M; Ohmachi, K; Terui, Y; Tobinai, K; Uchida, T; Uike, N; Uoshima, N; Usuki, K; Watanabe, T; Yamamoto, J | 1 |
| Alamdari, HS; Cassarino, DS; Chiu, MW; Pinter-Brown, L | 1 |
| Hardt, SE; Hosch, W; Katus, HA; Konstandin, MH; Korosoglou, G; Mereles, D | 1 |
| Cheson, B; Ujjani, C | 1 |
| Cheson, BD; Friedberg, JW; Kahl, BS; Tremmel, L; Van der Jagt, RH | 1 |
| Al-Batran, SE; Atmaca, A; Fauth, F; Jäger, E; Neumann, A; Pauligk, C; Weidmann, E | 1 |
| Ando, K; Matsumoto, Y; Ogura, M; Ohmachi, K; Taniwaki, M; Tobinai, K; Uchida, T; Watanabe, T | 1 |
| Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Wada, T | 1 |
| Albiero, E; Bernardi, M; Castegnaro, S; Chieregato, K; Madeo, D; Rodeghiero, F; Visco, C; Zanon, C | 1 |
| Engelhardt, M; Hieke, S; Horn, J; Kleber, M; Schmitt-Gräff, A; Wäsch, R | 1 |
| Korycka-Wołowiec, A; Robak, T | 1 |
| Dreyling, M; Gafter-Gvili, A; Gurion, R; Raanani, P; Shpilberg, O; Vidal, L | 1 |
| Boku, S; Hosoda, T; Kagoo, T; Ohashi, K; Ueno, H; Yamamoto, R; Yano, T; Yokoyama, A; Yoneda, M | 1 |
| Ogura, M | 1 |
| Feiten, S; Friesenhahn, V; Heymanns, J; Kleboth, K; Köppler, H; Thomalla, J; van Roye, C; Weide, R | 1 |
| Frickhofen, N; Hackenberg, U; Josten, KM; Jung, B; Kirchmaier, CM; Manner, H; Plum, N; Tonassi, L | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Rummel, MJ; Schneider, B; Seipelt, G; Sommerlad, WD; Weidmann, E | 1 |
| Gores, A; Heymanns, J; Köppler, H; Weide, R | 1 |
12 review(s) available for bendamustine hydrochloride and B-Cell Lymphoma
| Article | Year |
|---|---|
BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell; Prednisone; Quality of Life; Rituximab; Vincristine | 2023 |
Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Nitrogen Mustard Compounds | 2022 |
Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Comorbidity; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Treatment Outcome | 2017 |
Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Maintenance Chemotherapy; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Vincristine | 2019 |
Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hepatitis C, Chronic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Cirrhosis; Lymphoma, B-Cell; Lymphoma, Follicular; Middle Aged; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2013 |
[Development of cytomegalovirus antigenemia in 3 patients with B cell lymphoma treated with bendamustine monotherapy].
Topics: Adult; Aged; Antigens, Viral; Antiviral Agents; Bendamustine Hydrochloride; Biomarkers; CD4 Lymphocyte Count; Cytomegalovirus; Cytomegalovirus Infections; Female; Ganciclovir; Humans; Lymphoma, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Opportunistic Infections; Treatment Outcome; Valganciclovir; Virus Activation | 2014 |
[Recommendation for the optimal use of bendamustine in Japan].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Cytomegalovirus Infections; Drug Administration Schedule; Drug Eruptions; Evidence-Based Medicine; Hepatitis B; Humans; Immunocompromised Host; Japan; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Nausea; Nitrogen Mustard Compounds; Opportunistic Infections; Rituximab; Vasculitis | 2014 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Design; Drug Discovery; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2016 |
Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Rituximab | 2009 |
[Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2011 |
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Prednisone; Recurrence; Vincristine; Waldenstrom Macroglobulinemia | 2012 |
22 trial(s) available for bendamustine hydrochloride and B-Cell Lymphoma
| Article | Year |
|---|---|
Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bendamustine Hydrochloride; Humans; Ileus; Liposomes; Lymphoma, B-Cell; Lymphopenia; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rituximab; Vincristine | 2022 |
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Drug Therapy, Combination; Humans; Lymphoma, B-Cell | 2022 |
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Prognosis; Recurrence; Rituximab | 2023 |
Lymphocyte-monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low-grade B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Female; Humans; Lymphocyte Count; Lymphocytes; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Monocytes; Recurrence; Retrospective Studies | 2020 |
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Female; Humans; Italy; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Pilot Projects; Rituximab; Salvage Therapy; Treatment Outcome; Young Adult | 2018 |
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytomegalovirus Infections; Dexamethasone; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Rituximab; Salvage Therapy; Young Adult | 2019 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Immunoglobulin G; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Recombinant Fusion Proteins; Rituximab; Tetraspanins; Treatment Outcome | 2014 |
Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Bendamustine Hydrochloride; Female; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Taiwan | 2015 |
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Nitrogen Mustard Compounds; Treatment Outcome | 2015 |
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rituximab; Treatment Outcome; Young Adult | 2015 |
Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.
Topics: Bendamustine Hydrochloride; CD4-CD8 Ratio; Cytomegalovirus; Humans; Lymphoma, B-Cell; Neoplasm Grading; Remission Induction; Risk Factors; Virus Activation | 2016 |
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Thalidomide | 2016 |
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Female; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Recurrence; Retreatment; Rituximab; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome | 2016 |
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Gastrointestinal Diseases; Headache; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab | 2008 |
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Retreatment; Rituximab | 2010 |
Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Lung Diseases, Interstitial; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Neutropenia; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome | 2010 |
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Nitrogen Mustard Compounds; Pneumonia; Recurrence; Treatment Outcome; Vomiting | 2010 |
Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2011 |
Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell; Male; Neoplasm Staging; Neutropenia; Nitrogen Mustard Compounds; Rituximab | 2011 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy | 2002 |
38 other study(ies) available for bendamustine hydrochloride and B-Cell Lymphoma
| Article | Year |
|---|---|
Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Japan; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies; Rituximab; Salvage Therapy | 2021 |
Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Biomarkers, Tumor; China; Computational Biology; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome | 2022 |
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: A retrospective analysis of an administrative claims database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Case-Control Studies; Humans; Lymphoma, B-Cell; Neoplasms, Second Primary; Retrospective Studies; Rituximab | 2023 |
Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Frail Elderly; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Rituximab | 2023 |
[Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Protein Kinase Inhibitors; Rituximab; Treatment Outcome | 2023 |
[Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Datasets as Topic; Doxorubicin; Female; Humans; Lymphoma, B-Cell; Male; Medicare; Middle Aged; Neoplasms, Second Primary; Prednisone; Progression-Free Survival; Propensity Score; Registries; Rituximab; Treatment Outcome; United States; Vincristine | 2020 |
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Rituximab | 2020 |
[Bendamustine and rituximab combination therapy for recurrent indolent B-cell lymphomas: a retrospective single-institution study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab | 2020 |
Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bendamustine Hydrochloride; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell; Mice; Mice, Inbred NOD; MicroRNAs; Molecular Targeted Therapy; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-myc; Repressor Proteins; Signal Transduction; Survival Analysis; Tumor Burden; Vorinostat; Xenograft Model Antitumor Assays | 2021 |
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Greece; Humans; Immunoconjugates; Lymphoma, B-Cell; Male; Middle Aged; Rituximab; Survival Rate | 2021 |
Long-term safety experience with bendamustine for injection in a real-world setting.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Pharmacovigilance; Product Surveillance, Postmarketing | 2017 |
Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Administration Schedule; Female; Follow-Up Studies; Ganciclovir; Humans; Injections, Intravenous; Intravitreal Injections; Japan; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Opportunistic Infections; Retrospective Studies | 2017 |
Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma.
Topics: Bendamustine Hydrochloride; Female; Humans; Immunophenotyping; Lacrimal Apparatus; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Middle Aged; Remission Induction; Rituximab; Subcutaneous Tissue | 2017 |
Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Infections; Lymphoma, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
CMV Pneumonitis following Bendamustine containing Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Lymphoma, B-Cell; Pneumonia, Viral; Virus Activation | 2017 |
Single centre study of using bendamustine in the treatment of B-cell malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Remission Induction; Retrospective Studies; Treatment Outcome | 2013 |
Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Line, Tumor; Humans; Imidazoles; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Proto-Oncogene Proteins c-pim-1; Pyridazines | 2013 |
Simultaneous determination of bendamustine and its active metabolite, gamma-hydroxy-bendamustine in human plasma and urine using HPLC-fluorescence detector: application to a pharmacokinetic study in Chinese cancer patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; China; Chromatography, High Pressure Liquid; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Reproducibility of Results; Sensitivity and Specificity | 2014 |
Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy.
Topics: Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Fatal Outcome; Humans; Lymphoma, B-Cell; Male; Rituximab; Stevens-Johnson Syndrome | 2015 |
Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Grading; Nitrogen Mustard Compounds; Retrospective Studies; Virus Activation | 2015 |
Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine.
Topics: Adult; Aged; Bendamustine Hydrochloride; Biomarkers; CD8-Positive T-Lymphocytes; Drug Eruptions; Eosinophils; Female; Humans; Leukocyte Count; Lymphoma, B-Cell; Male; Middle Aged; Skin Diseases; Treatment Outcome | 2015 |
Adequacy of peripheral blood stem cell mobilization in patients with relapsed B-cell non-Hodgkin lymphoma treated with bendamustine.
Topics: Bendamustine Hydrochloride; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cells; Recurrence; Transplantation, Autologous; Treatment Outcome | 2016 |
Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab | 2015 |
[Progress of bendamustine in the treatment of B cell non-Hodgkin lymphoma].
Topics: Bendamustine Hydrochloride; Humans; Lymphoma, B-Cell | 2015 |
Intravascular large B-cell lymphoma: successful therapy with bendamustine and rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Blood Vessels; Drug Therapy, Combination; Female; Humans; Lymphocytes; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Skin Neoplasms | 2009 |
Severe cutaneous interface drug eruption associated with bendamustine.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Drug Eruptions; Humans; Lymphoma, B-Cell; Male; Nitrogen Mustard Compounds; Prednisone; Vincristine | 2010 |
Severe right ventricular outflow tract obstruction caused by non-hodgkin lymphoma: complete regression after one course of bendamustine/rituximab therapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Diagnosis, Differential; Drug Therapy, Combination; Echocardiography; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Recovery of Function; Rituximab; Severity of Illness Index; Tomography, X-Ray Computed; Ventricular Function, Right; Ventricular Outflow Obstruction | 2011 |
Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Nausea; Nitrogen Mustard Compounds; Rituximab; Survival Analysis; Treatment Outcome | 2010 |
Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Rituximab | 2011 |
Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cytarabine; Humans; Leukemia; Leukemia, B-Cell; Leukemia, T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Nitrogen Mustard Compounds | 2012 |
Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Tolerance; Female; Follow-Up Studies; Frail Elderly; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Invasiveness; Nitrogen Mustard Compounds; Rituximab; Survival Rate; Treatment Outcome | 2012 |
Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies.
Topics: Administration, Intravenous; Antineoplastic Agents; B-Lymphocytes; Bendamustine Hydrochloride; Drug Evaluation; Europe; Humans; Japan; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; United States | 2012 |
Bendamustine can severely impair T-cell immunity against cytomegalovirus.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; T-Lymphocytes | 2013 |
Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Retreatment; Treatment Outcome | 2013 |
Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Antineoplastic Agents; Antiphospholipid Syndrome; Bendamustine Hydrochloride; Female; Heparin, Low-Molecular-Weight; Humans; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Rituximab; Splenic Neoplasms | 2008 |
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Burkitt Lymphoma; Caspase 7; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cladribine; Complement Activation; Complement System Proteins; Cysteine Proteinase Inhibitors; Doxorubicin; Drug Synergism; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Rabbits; Rituximab; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |